Navigation Links
Cleveland Clinic researchers honored for contributions to science and technology
Date:2/24/2011

Wednesday, February 23, 2011 Cleveland Three Cleveland Clinic researchers were recently named as Fellows of the American Association for the Advancement of Science (AAAS), which seeks "to advance science, engineering, and innovation throughout the world for the benefit of all people."

The following individuals were recognized for their contributions to science and technology at the Fellows Forum on February 19, 2011, during the AAAS Annual Meeting in Washington, D.C.:

  • Thomas A. Hamilton, Ph.D., Chair, Immunology, Lerner Research Institute;
  • Qing Kenneth Wang, Ph.D., Molecular Cardiology, Lerner Research Institute;
  • Ram Ganapathi, Ph.D., Translational Hematology and Oncology Research, Taussig Cancer Institute.

Hamilton and Wang were elected Fellows under the AAAS's Section on Medical Sciences, and Ganapathi was elected as a Fellow under the Section on Pharmaceutical Sciences.

AAAS states: "Election as a Fellow of AAAS is an honor bestowed upon members by their peers. Fellows are recognized for meritorious efforts to advance science or its applications."

Hamilton was recognized for contributions to the understanding of inflammatory processes, particularly at the level of cytokine and chemokine gene expression and mRNA stabilization. "We continue to work toward definition of the molecular events that control the expression of inducible genes during the initiation and resolution of both inflammation and cell stress responses," Hamilton said. "Specifically these studies focus upon alterations in transcription and mRNA metabolism that can produce significant changes in levels of gene products that have important roles in coordinating the outcome of injury."

Wang was recognized for the discovery of the first gene for the lethal heart rhythm disorder Brugada syndrome, identification of mechanisms of channelopathies, and fundamental contributions to the field of arrhythmias, seizures, and sudden death. "We have identified nine genes that cause various cardiovascular and neurological diseases," said Wang, who is also Professor of Molecular Medicine at Cleveland Clinic Lerner College of Medicine and Professor of Genetics at Case Western Reserve University.

Ganapathi was recognized for contributions in the field of cancer pharmacology, molecular prognostication and anti-cancer drug development. "We continue our work on clinically active anti-tumor drugs to determine the mechanism of action and pathways of resistance, so that pharmacogenomics and targeted approaches can be exploited to maximize efficacy and reduce toxicity of chemotherapy in the treatment of cancer," said Ganapathi, who is Director of Clinical Pharmacology at the Cleveland Clinic Taussig Cancer Institute and Professor of Medicine in the Cleveland Clinic Lerner College of Medicine.


'/>"/>

Contact: Dan Doron
dorond@ccf.org
216-312-0428
Lerner Research Institute
Source:Eurekalert

Related biology news :

1. Draft sequence of Neandertal genome wins the 2010 AAAS Newcomb Cleveland Prize, supported by Affymetrix
2. Cleveland Museum of Natural History scientist announces new horned dinosaur
3. Cleveland Clinic, CWRU dental researcher finds switch that turns on the spread of cancer
4. Preview of oral presentations at the 1st IOF-ESCEO Pre-Clinical Symposium
5. Press registration open for clinical nutrition conference
6. Clinical Benefits of Zimmers DeNovo® NT Natural Tissue Graft in First Surgery Documented in Peer-Reviewed Publication
7. Media alert: ACMG 2011 Clinical Genetics Meeting -- press registration is now open
8. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
9. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
10. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
11. Cornell Dots that light up cancer cells go into clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... Mass. , Nov. 30, 2016   Merck ... that it has entered into a set of agreements ... services for Merck,s collection of genetic reagents such as ... with Evotec,s screening expertise offers an accelerated pathway to ... discovery starts with the identification of new targets, a ...
(Date:11/30/2016)... ... November 30, 2016 , ... Energetiq Technology, a world leader ... generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at the MRS Fall Exhibit 2016. ... offers higher radiance and irradiance from a truly broadband white light source. The ...
(Date:11/30/2016)... ... November 30, 2016 , ... On 28 November 2016, the International Union ... nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, ... earlier proposed by the discoverers have been approved by the IUPAC Bureau. The IUPAC ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... of precision treatments for neurodegenerative diseases, today announced that all five of its ... 3, 2016) blocked propagation of toxic, prion-like forms of Amyloid beta (Aß) in ...
Breaking Biology Technology: